4 completed, 3 terminated, 2 withdrawn, 1 suspended. 10 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 3, Terminated 3, Withdrawn 2, Suspended 1, Unknown 1 |
| Phase 1 | 5 | Completed 2, Suspended 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 1 | Unknown 1 |
Follow E-3810: new trials by email Literature Review of E-3810 trials Research Report on E-3810
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy nivolumab, ipilimumab, cabozantinib - Carcinoma, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Withdrawn | Bristol-Myers Squibb | 2021-04-15 | 2023-12-19 | |
| This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients AL3810, carboplatin + etoposide, Placebo - Extensive-stage Small Cell Lung Cancer | Phase 2 / Phase 3 | Unknown | Haihe Biopharma Co., Ltd. | 313 | 2019-11-14 | 2020-02-05 |
| A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor Lucitanib, Nivolumab - Advanced Solid Tumor, Gynecologic Cancer | Phase 1 / Phase 2 | Suspended | Clovis Oncology, Inc. | 227 | 2019-07-29 | 2022-12-20 |
| A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) Rucaparib, Lucitanib, Sacituzumab govitecan - Ovarian Cancer, Triple-negative Breast Cancer | Phase 1 / Phase 2 | Terminated | pharmaand GmbH | 25 | 2019-06-28 | 2024-01-16 |
| Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After Chemotherapy lucitanib 15 mg QD, lucitanib 10 mg QD, placebo QD - Advanced Thymic Carcinoma | Phase 2 | Completed | Haihe Biopharma Co., Ltd. | 74 | 2018-08-16 | 2026-09-17 |
| Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations Lucitanib - Advanced Cancer | Phase 2 | Withdrawn | Teresa Helsten, MD | 2017-04-01 | 2018-08-02 | |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Lucitanib - Breast Cancer, Metastatic Breast Cancer | Phase 2 | Terminated | Clovis Oncology, Inc. | 178 | 2014-09-09 | 2020-06-23 |
| A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations Lucitanib - Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer | Phase 2 | Terminated | Clovis Oncology, Inc. | 18 | 2014-04-01 | 2019-07-29 |
| Study of the AL3810 in the Treatment of Advanced Solid Tumor Lucitanib - Advanced Solid Tumors | Phase 1 | Completed | Haihe Biopharma Co., Ltd. | 17 | 2014-03-01 | 2017-04-17 |
| A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer lucitanib - Breast Cancer | Phase 2 | Completed | Institut de Recherches Internationales Servier | 76 | 2013-12-01 | 2024-07-25 |
| Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors Lucitanib - Solid Tumors | Phase 1 / Phase 2 | Completed | Institut de Recherches Internationales Servier | 134 | 2010-07-01 | 2024-07-25 |
Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Ovarian Neoplasms (2) · Small Cell Lung Carcinoma (2) · Acrocephalosyndactylia (1) · Carcinoma (1) · Carcinoma, Transitional Cell (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Genital Neoplasms, Female (1) · Lung Neoplasms (1) · Neoplasms (1) · Thymoma (1) · Triple Negative Breast Neoplasms (1) · Uterine Cervical Neoplasms (1)
Clovis Oncology, Inc. (3) · Haihe Biopharma Co., Ltd. (3) · Institut de Recherches Internationales Servier (2) · Bristol-Myers Squibb (1) · Teresa Helsten, MD (1) · pharmaand GmbH (1)
United States (6) · Italy (4) · Spain (4) · Belgium (3) · China (3) · France (3) · Germany (3) · Argentina (1) · Australia (1) · Austria (1) · Canada (1) · Denmark (1) · Greece (1) · Hungary (1) · Mexico (1)
Erika Hamilton, MD (1) · Huiming Cai, MD (1) · Javier Cortes, MD (1) · Jin Li, M.D. (1) · Junning Cao, M.D. (1) · Nicole Concin, MD (1) · Teresa Helsten, MD (1)
2018 (2)